| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Penumbra, Inc.$319.49
+0.76 (+0.24%)
D 35Pipeline Score MedTech · Commercial
Market Cap
12.93 B
EPS
4.38
P/E Ratio
75.63 $
Value Trade
128.50 M
SEC Financials
Q1 2026Dilution Risk
Revenue
374.76 M
R&D Expenses
22.38 M
Operating CF
86.97 M
Total Assets
1.90 B
Total Liabilities
424.63 M
Equity
1.47 B
D/E Ratio
12,345
1.7 %
Week
-0.74 %
1 Month
-3.61 %
3 Month
17.52 %
6 Month
29.16 %
5 Year
721.73 %
All Time
Cash Data
Cash Position
615.66 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
338.84 K
52 Week Range
221.26 - 362.41
% held by Insiders
2.82 %
% held by Institutions
86.04 %
Enterprise Value
12.53 B
Total Shares
39.32 M
Short %
5.56 %
Float Shares
38.18 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D35
Pipeline Score $577M
Pipeline ValueValuation Signal
1
Drugs Scored0.2x
rNPV / MCap Top 50%
Mid Cap (rank 457 of 913)
Percentile RankPenumbra, Inc. faces pipeline headwinds (35/100), with $679M risk-adjusted pipeline value, led by Penumbra System in Stroke (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Penumbra System Unknown | Stroke | Phase 2 | NCT00334061 | 12% | $679M | COMPLETED | 125 | - | - | Nov 1, 2007 | - | Sep 18, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
computer assisted vacuum thrombectomy (CAVT) | pulmonary embolism | — | 2026-04-14 | greater functional improvement; walking significantly further; higher proportion of patients achieving NYHA Class I Read More | New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients Read More | |
computer assisted vacuum thrombectomy (CAVT) | pulmonary embolism | — | 2026-04-14 | greater functional improvement; walking significantly further; higher proportion of patients achieving NYHA Class I Read More | New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients Read More | |
computer assisted vacuum thrombectomy (CAVT) | pulmonary embolism | — | 2026-04-14 | greater functional improvement; walking significantly further; higher proportion of patients achieving NYHA Class I Read More | New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PEN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PEN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PENTHUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
The THUNDER study has shown that Penumbra's THUNDERBOLT device is both safe and effective for treating stroke patients with emergent large vessel occlusion. The device demonstrated a high rate of complete clot ingestion and low complication rates. With a median time-to-revascularization of just 20 minutes, the study results support the advancement of mechanical thrombectomy technologies. THUNDERBOLT has also received FDA clearance and CE Mark.
Read more →PENFirst Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
Penumbra, Inc. has initiated its FORWARD study, focusing on mechanical thrombectomy for distal acute ischemic strokes. The study aims to evaluate the safety and efficacy of its RED reperfusion catheter portfolio, which includes the THUNDERBOLT CAVT platform. The first patient has been treated, marking a key milestone in addressing a challenging patient population with limited treatment options.
Read more →PENPenumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT
Penumbra, Inc. has received CE Mark approval for its THUNDERBOLT technology, which enables advanced computer-assisted vacuum thrombectomy for acute ischemic stroke. This marks a significant step in expanding access to innovative stroke care in Europe, following recent FDA clearance in the U.S. The technology aims to enhance patient outcomes and streamline treatment procedures.
Read more →PENPenumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
Penumbra, Inc. has received FDA clearance for its THUNDERBOLT technology, the first computer-assisted vacuum thrombectomy platform aimed at treating acute ischemic stroke. This innovative system enhances clot removal efficiency and safety, potentially improving patient recovery outcomes. THUNDERBOLT is set to redefine stroke management by minimizing catheter manipulation and ensuring complete clot capture.
Read more →PENPenumbra, Inc. Reports First Quarter 2026 Financial Results
Penumbra, Inc. reported strong financial results for Q1 2026, with revenues reaching $374.8 million, a 15.6% increase from the previous year. The company saw significant growth in both thrombectomy and embolization revenues. However, it has opted not to provide financial guidance for the full year due to its pending acquisition by Boston Scientific Corporation.
Read more →PENNew STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients
Penumbra, Inc. announced positive 90-day results from the STORM-PE trial, indicating that patients with acute intermediate-high risk pulmonary embolism (PE) who received computer-assisted vacuum thrombectomy (CAVT) alongside anticoagulation experienced better functional outcomes than those treated with anticoagulation alone. The trial demonstrated significant improvements in walking distance and overall patient functionality. Safety profiles were comparable between both treatment groups.
Read more →PENPenumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Penumbra, Inc. reported strong financial results for Q4 and the full year of 2025, with total revenue reaching $385.4 million in Q4, up 22.1% year-over-year. The company's gross profit margin improved, and income from operations increased significantly. However, the pending acquisition by Boston Scientific has led to the decision not to provide financial guidance for 2026.
Read more →PENPenumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results
Penumbra, Inc. has released preliminary financial results for the fourth quarter and full year of 2025. The company continues to establish itself as a leader in thrombectomy technology, focusing on innovative solutions for serious medical conditions. Their efforts are aimed at enhancing patient outcomes across more than 100 countries.
Read more →PENPenumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
Penumbra, Inc. has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 12, 2026. The presentation will be available via a webcast on the company's website, which will remain accessible for at least two weeks post-event. Penumbra is known for its innovative thrombectomy technologies aimed at improving patient care.
Read more →PENPenumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference
Penumbra, Inc. announced that its management team will present at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. The presentation will be accessible via a webcast on the company's website, which will remain available for two weeks post-event. Penumbra focuses on innovative thrombectomy technologies aimed at improving patient outcomes.
Read more →PEN▲ +17.3%on this news
Penumbra, Inc. Reports Third Quarter 2025 Financial Results
Penumbra, Inc. reported strong financial results for Q3 2025, with total revenue reaching $354.7 million, a 17.8% increase from the previous year. The company also raised its full-year revenue guidance to between $1.375 billion and $1.380 billion, reflecting confidence in continued growth. Gross profit margin improved to 67.8%, although operating expenses rose compared to the prior year.
Read more →PENLatest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism
Penumbra, Inc. announced positive results from the STORM-PE trial, showing that computer-assisted vacuum thrombectomy (CAVT) combined with anticoagulation significantly improves functional outcomes for patients with acute pulmonary embolism. The trial demonstrated superior thrombus reduction and recovery rates compared to anticoagulation alone. These findings highlight the importance of early intervention and may influence future treatment guidelines.
Read more →PENLandmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism
Penumbra, Inc. announced positive results from the STORM-PE trial, demonstrating that computer assisted vacuum thrombectomy (CAVT) combined with anticoagulation significantly reduces right heart strain in patients with acute pulmonary embolism compared to anticoagulation alone. The study involved 100 patients across 22 sites and showed a higher rate of normalization of RV/LV ratio without increased complications. These findings could influence future treatment guidelines for pulmonary embolism.
Read more →PENPenumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025
Penumbra, Inc. will host an investor event on October 26, 2025, at the TCT Conference, focusing on the STORM-PE clinical trial. A conference call for third quarter financial results is scheduled for November 5, 2025. The events will be accessible via webcast, emphasizing the company's commitment to transparency and investor engagement.
Read more →PENPenumbra, Inc. Names Shruthi Narayan as Company President
Penumbra, Inc. has announced the promotion of Shruthi Narayan to President, effective September 1, 2025. Narayan, a seasoned leader with 20 years in the medical device industry, previously led the company's interventional business. Her appointment is expected to drive continued growth and innovation in Penumbra's life-saving technologies.
Read more →PENPenumbra, Inc. to Present at Upcoming Investor Conferences
Penumbra, Inc. has announced its participation in two upcoming investor conferences: the Wells Fargo Healthcare Conference on September 3, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. The presentations will be accessible via webcasts on the company's website for at least two weeks after each event. Penumbra is known for its advancements in thrombectomy technologies.
Read more →PENPenumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference
Penumbra, Inc. announced its participation in the Canaccord Genuity 45th Annual Growth Conference, scheduled for August 12, 2025. The presentation will be accessible via a webcast, allowing investors to engage with the company's updates. Penumbra is known for its innovative thrombectomy technologies aimed at improving patient outcomes.
Read more →PENPenumbra, Inc. Reports Second Quarter 2025 Financial Results
Penumbra, Inc. reported strong financial results for the second quarter of 2025, with total revenue reaching $339.5 million, up 13.4% from the previous year. Key drivers included a 22.6% increase in U.S. thrombectomy revenue, contributing significantly to the overall growth. The company also increased its full-year revenue guidance to between $1 billion, 355 million and $1 billion, 370 million, reflecting an optimistic outlook for growth in 2025. Moreover, net income for the quarter was reported at $45.3 million.
Read more →PENPenumbra, Inc. Reports Second Quarter 2025 Financial Results Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025....
Penumbra, Inc. reported a strong financial performance for Q2 2025, with revenues reaching $339.5 million, a 13.4% increase from the previous year. The U.S. thrombectomy segment saw significant growth, contributing $188.5 million to total revenue. The company also reported a net income of $45.3 million, reflecting improved operational efficiency. Additionally, Penumbra raised its full-year revenue guidance, anticipating continued growth in its core markets.
Read more →PENPenumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025
Penumbra, Inc. has announced a conference call scheduled for July 29, 2025, to discuss its financial results for the second quarter of 2025. The call will take place after market close and will be accessible via phone and webcast. The company continues to lead in thrombectomy technology, focusing on improving patient outcomes.
Read more →PENPenumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial
Penumbra, Inc. has successfully completed enrollment for the STORM-PE clinical trial, which evaluates the effectiveness of computer assisted vacuum thrombectomy (CAVT) versus anticoagulation alone in treating acute intermediate-high risk pulmonary embolism. The trial enrolled 100 patients and aims to provide high-quality evidence to inform treatment guidelines. This milestone highlights Penumbra's commitment to advancing care for patients with pulmonary embolism.
Read more →PENPenumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest...
Penumbra, Inc. has received FDA clearance for its Ruby® XL System, the longest and softest coil available for vascular embolization. The new system is designed for enhanced efficiency in embolization procedures, which could potentially reduce radiation exposure for patients. It incorporates several unique technologies that allow for greater volume and procedural flexibility. The Ruby XL System strengthens Penumbra's existing portfolio of embolization products, presenting significant enhancements for healthcare providers.
Read more →PENPenumbra, Inc. to Present at Upcoming Investor Conferences Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and...
Penumbra, Inc. (NYSE: PEN) has announced that its management team will present at several upcoming investor conferences, including the William Blair Annual Growth Stock Conference and the Jefferies Global Healthcare Conference. These presentations will provide an opportunity for the company to showcase its innovations in thrombectomy technology. Webcasts of the presentations will be accessible on the company’s website for at least two weeks after each event.
Read more →PENPenumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on...
Penumbra, Inc. has announced that its management will present at the BofA Securities 2025 Health Care Conference on May 13, 2025. This event will be accessible via a webcast on the company's website and will remain available for two weeks post-event. Penumbra is recognized as a leader in thrombectomy technologies, focusing on innovative solutions for various medical conditions, including ischemic stroke and acute limb ischemia.
Read more →PENPenumbra, Inc. Reports First Quarter 2025 Financial Results Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025....
Penumbra, Inc. reported strong financial results for Q1 2025, with revenues of $324.1 million, reflecting a 16.3% increase compared to the previous year. The U.S. thrombectomy segment saw a notable growth of 25.0%. The company's net income also rose significantly to $39.2 million. Additionally, Penumbra has updated its revenue guidance for the full year 2025, indicating continued optimism in its performance.
Read more →PENPenumbra, Inc. Reports First Quarter 2025 Financial Results
Penumbra, Inc. has announced its financial results for the first quarter of 2025, reporting a revenue of $324.1 million, a 16.3% increase from the prior year. U.S. thrombectomy revenue demonstrated particularly strong growth, climbing 25.0%. The company also noted improved operating income of $40.4 million and a continued positive outlook for revenue growth and gross margin expansion throughout the year. Penumbra maintains its revenue guidance for 2025, expecting total revenue between $1,340 million and $1,360 million.
Read more →PENPenumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market...
Penumbra, Inc. announced its plans to host a conference call on April 23, 2025, to discuss the financial results for the first quarter of 2025. The call will take place after market close, with a press release providing detailed results released at that time. Interested parties can access the call via phone or webcast, which will also be available for two weeks following the event.
Read more →PENSeven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data...
Penumbra, Inc. announced seven significant presentations regarding its computer assisted vacuum thrombectomy (CAVT) technology at the 2025 Society of Interventional Radiology Annual Scientific Meeting. The data indicates that CAVT improves patient outcomes and reduces healthcare costs, supporting its use as a frontline therapy for blood clots. Highlighted studies demonstrate the safety and effectiveness of CAVT in various conditions, including pulmonary embolism and lower extremity acute limb ischemia. The findings are significant for advocating CAVT's broad utility and potential benefits in healthcare economics.
Read more →PENPenumbra, Inc. Announces Don Kassing will Retire from Board of Directors Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has...
Penumbra, Inc. announced the retirement of Don Kassing from its Board of Directors effective April 1, 2025, after 17 years of service. Kassing has been commended for his wisdom and leadership, particularly during the company’s expansion. He has held various positions, including Presiding Director since 2015, and has a significant background in higher education and finance. Penumbra is focused on developing technologies for treating complex medical conditions.
Read more →PENPenumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended...
Penumbra, Inc. reported strong financial results for Q4 and full year 2024, with adjusted revenue increasing by 12.9% year-over-year. The company anticipates continued growth in 2025, particularly in its U.S. thrombectomy franchise. However, international revenue faced a decline, and net income saw a significant drop compared to the previous year, influenced by various one-time charges and impairments.
Read more →PENPenumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
Penumbra, Inc. reported strong financial results for Q4 and the full year 2024, with adjusted revenues of $321.3 million for the fourth quarter and $1,200.4 million for the year, marking significant increases compared to 2023. Sales of thrombectomy products surged in the U.S., contributing to a net income of $33.7 million in Q4. However, international revenue saw a decline, which raised some concerns about growth outside the U.S. Global revenue from embolization and access products also fell slightly, demonstrating mixed performance across categories.
Read more →PENPenumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 ...
Penumbra, Inc. has scheduled a conference call for February 18, 2025, after market close, to discuss its financial results for the fourth quarter and full year 2024. A press release with the financial results will be available prior to the call. The webcast will be accessible for at least two weeks following the call on the company's website. Penumbra is recognized as a leader in thrombectomy technologies, improving patient care through innovative solutions.
Read more →PENPenumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on...
Penumbra, Inc. has announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. This event highlights the company's commitment to engaging with the investor community and sharing updates on its innovative thrombectomy technologies. The presentation can be accessed via a webcast on Penumbra's website, which shows their dedication to transparency and communication. The company is known for developing technologies aimed at improving outcomes for serious medical conditions.
Read more →PENPenumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on ...
Penumbra, Inc. has announced that its management team will present at the Piper Sandler 36th Annual Healthcare Conference scheduled for December 4, 2024. The presentation will be accessible via webcast, emphasizing the company's commitment to transparency and investor relations. Penumbra is recognized as a leader in thrombectomy technology, aiming to improve outcomes in various medical conditions. More information about the event and the company's innovations can be found on their website.
Read more →PENNew Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced new data that demonstrate patients with intermediate-risk pulmonary...
Penumbra, Inc. (NYSE: PEN) recently presented data demonstrating that patients with intermediate-risk pulmonary embolism (PE) treated with their computer assisted vacuum thrombectomy (CAVT) technology have shorter hospital stays and fewer complications compared to other treatments. The study indicates that CAVT not only improves patient outcomes but could also reduce healthcare costs by ensuring better resource utilization. This analysis, based on a large sample through the Vizient Clinical Data Base, highlights the growing preference for CAVT in clinical settings.
Read more →PENPenumbra, Inc. Reports Third Quarter 2024 Financial Results
Penumbra, Inc. reported its financial results for the third quarter of 2024, showing a total revenue increase to $301.0 million, up 11.1% from the previous year. The U.S. contributed significantly, with thrombectomy revenue rising by 21.2%. Despite these positive results, international revenue saw a slight decline. The company has reiterated its full-year revenue guidance and expects continued growth in its U.S. franchises.
Read more →PENPenumbra, Inc. Reports Third Quarter 2024 Financial Results Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2024....
Penumbra, Inc. reported strong financial results for Q3 2024, with total revenue reaching $301 million, a significant 11.1% increase from the previous year. The U.S. thrombectomy segment saw a remarkable 21.2% growth, contributing to a net income of $29.5 million. However, international revenue declined slightly, and the company incurred one-time expenses related to its Immersive Healthcare business. Looking ahead, Penumbra anticipates continued growth in its U.S. thrombectomy franchise.
Read more →PENPenumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for...
Penumbra, Inc. has announced the completion of enrollment in the THUNDER clinical study aimed at evaluating its innovative Thunderbolt technology for treating acute ischemic stroke. This study includes patients with intracranial large vessel occlusion who are eligible for mechanical thrombectomy. The primary endpoint focuses on the effectiveness of revascularization immediately following the procedure. The company emphasizes that this advancement is a crucial step in enhancing stroke management and improving patient outcomes.
Read more →PENPenumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2024 after market...
Penumbra, Inc. has announced a conference call scheduled for October 30, 2024, to discuss its financial results for the third quarter of 2024. The call will take place after market close at 4:30 PM Eastern Time, and a press release with the results will be issued at that time. Investors can access the call through phone or webcast, with the archive available for two weeks post-event. The company focuses on innovative thrombectomy technologies to improve medical outcomes globally.
Read more →PENPenumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash™ 2.0 and Lightning Bolt™ 7 - in Europe Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer...
Penumbra, Inc. announced the receipt of CE Mark certification for its new computer assisted vacuum thrombectomy technologies, Lightning Flash™ 2.0 and Lightning Bolt™ 7, which are now the only systems of their kind available in Europe. These devices are designed to improve the efficiency and safety of clot removal procedures in vascular patients. Feedback from medical professionals indicates strong confidence in the advancements provided by these technologies to significantly enhance patient outcomes in managing conditions like pulmonary embolism and acute limb ischemia.
Read more →PENPenumbra, Inc. to Present at the Baird Global Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Baird Global Healthcare Conference on Tuesday,...
Penumbra, Inc. has announced that its management team will present at the Baird Global Healthcare Conference on September 10, 2024. The event aims to highlight the company's innovative approaches in treating challenging medical conditions, including ischemic stroke and venous thromboembolism. A webcast of the presentation will be available for two weeks on the company's website, allowing broader access to interested stakeholders.
Read more →PENPenumbra, Inc. to Present at the Wells Fargo Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Wells Fargo Healthcare Conference on Wednesday,...
Penumbra, Inc. is set to present at the Wells Fargo Healthcare Conference on September 4, 2024. This engagement reflects the company's ongoing commitment to sharing advancements in thrombectomy technology. Attendees will have the opportunity to access the presentation via a webcast available on Penumbra's website. The company emphasizes its role in addressing critical medical conditions and improving patient care globally.
Read more →PEN▲ +10.8%on this news
Penumbra, Inc. Announces $200 Million Share Repurchase Authorization Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced that its Board of Directors approved on August 5, 2024 a share...
Penumbra, Inc. has announced a $200 million share repurchase program, with an initial $100 million designated for an accelerated share repurchase agreement with JPMorgan Chase. The Board of Directors approved this initiative to enhance shareholder value, allowing shares to be repurchased through various means until July 31, 2025. The initial share delivery is set for August 13, 2024, with further adjustments based on stock performance. Funding for the repurchase will come from the company's cash reserves.
Read more →PENPenumbra, Inc. to Present at the Canaccord Genuity Growth Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity Growth Conference on Tuesday,...
Penumbra, Inc. announced its participation in the Canaccord Genuity Growth Conference scheduled for August 13, 2024. The company's management will present innovative thrombectomy technologies aimed at treating conditions like ischemic stroke and acute limb ischemia. A webcast of the presentation will be available on the company's website for two weeks post-event. Penumbra remains a key player in advancing healthcare solutions across the globe.
Read more →PENPenumbra, Inc. Reports Second Quarter 2024 Financial Results Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter...
Penumbra, Inc. reported its second quarter 2024 financial results, showcasing a revenue increase of 14.5% to $299.4 million. U.S. thrombectomy sales surged by 24.9%, contributing significantly to overall growth. However, the company faced an operational loss of $81 million due to impairment charges and has revised its revenue guidance downward for the year. Despite challenges, adjusted EBITDA showed improvement, reflecting a positive trend in profitability.
Read more →PENPenumbra, Inc. Reports Second Quarter 2024 Financial Results
Penumbra, Inc. reported its second quarter financial results for 2024, showcasing a revenue increase of 14.5% year-over-year, reaching $299.4 million. The company experienced significant growth in U.S. thrombectomy revenue, but also reported a substantial loss from operations attributed to large one-time impairment charges. Additionally, Penumbra updated its full year 2024 revenue guidance downward by $60 million, highlighting challenges in the China and European markets. Despite these setbacks, non-GAAP profitability measures showed improvements.
Read more →PENPenumbra, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call for July 30, 2024 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2024 after market...
Penumbra, Inc. has announced a conference call scheduled for July 30, 2024, to discuss its financial results for the second quarter of 2024. The call will take place at 4:30 PM Eastern Time, with a press release issued after market close on the same day. Investors can participate via phone or access a webcast of the event on the company’s website. This reflects the company's commitment to keeping stakeholders informed.
Read more →PENPenumbra, Inc. to Present at the Truist Securities MedTech Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Truist Securities MedTech Conference on Tuesday,...
Penumbra, Inc. announced its participation in the Truist Securities MedTech Conference scheduled for June 18, 2024. The company's management team will present insights regarding their innovations in healthcare. A webcast of the presentation will be available on their website following the event, ensuring broader access for interested stakeholders. Penumbra continues to focus on addressing significant unmet medical needs through its diverse product offerings.
Read more →PENPenumbra, Inc. to Present at the William Blair Growth Stock Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair Growth Stock Conference on Thursday, ...
Penumbra, Inc. has announced that its management team is scheduled to present at the William Blair Growth Stock Conference on June 6, 2024. The event aims to highlight the company's innovative therapies and its extensive product portfolio. Interested stakeholders can access a webcast of the presentation on the company's website. This conference represents a platform for Penumbra to engage with investors and emphasize its contributions to healthcare.
Read more →PENPenumbra, Inc. Reports First Quarter 2024 Financial Results
Penumbra, Inc. reported strong financial results for the first quarter of 2024, with a revenue increase of 15.4% year-over-year, totaling $278.7 million. Notably, U.S. thrombectomy sales surged by 35.2%, reflecting robust demand for their products. The company continues to project substantial growth for the full year, reiterating guidance for total revenue between $1.23 billion and $1.27 billion. However, there were declines in international revenue in certain product segments, indicating some challenges in the global market.
Read more →PENPenumbra, Inc. Reports First Quarter 2024 Financial Results Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended ...
Penumbra, Inc. reported a strong financial performance for Q1 2024, with total revenue reaching $278.7 million, a 15.4% increase from Q1 2023. The U.S. thrombectomy segment showed remarkable growth, contributing $150.3 million, up 35.2%. Despite some declines in international sales and embolization products, the company maintains a positive outlook for the full year, projecting revenue growth of 16-20%. Adjusted EBITDA also improved, reflecting operational efficiency.
Read more →PENPenumbra, Inc. to Present at the RBC Capital Markets Global Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the RBC Capital Markets Global Healthcare Conference...
Penumbra, Inc. has announced its participation in the RBC Capital Markets Global Healthcare Conference, scheduled for May 15, 2024. The company's management team will present updates on their innovative therapies and product portfolio. Interested parties can access a webcast of the presentation via the company's website, which will remain available for two weeks post-event. Penumbra's commitment to addressing challenging medical conditions is evident in their global outreach to healthcare providers across over 100 countries.
Read more →PENPenumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots Penumbra, Inc. (NYSE: PEN), the world's largest thrombectomy company, announced the U.S. Food and Drug Administration (FDA) clearance and launch of...
Penumbra, Inc. has announced the FDA clearance and launch of Lightning Flash 2.0, an advanced computer-assisted vacuum thrombectomy system designed to effectively remove blood clots and treat pulmonary emboli. This new device includes significant improvements such as faster procedure times and reduced blood loss. The Lightning Flash 2.0 incorporates advanced algorithms and catheter technology, enhancing physicians' ability to navigate complex anatomical structures. Penumbra's commitment to innovation aims to transform patient care and improve clinical outcomes in thrombectomy procedures.
Read more →PENPenumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2024 after market...
Penumbra, Inc. has announced a conference call to discuss its financial results for the first quarter of 2024, which will take place on May 7, 2024, at 4:30 PM Eastern Time. A press release detailing the financial results will be issued after market close on that day. The call can be accessed via phone or a webcast, which will be available on the company's website for at least two weeks. This event reflects Penumbra's ongoing engagement with its investors and transparency regarding its financial performance.
Read more →PENPenumbra, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
Penumbra, Inc. reported robust financial results for Q4 2023 and the full year 2023, showing significant revenue growth attributed primarily to its thrombectomy products. The company's Q4 revenue reached $284.7 million, marking a 28.7% increase from the previous year's quarter. Penumbra anticipates continued growth in 2024, forecasting total revenue growth between 16% to 20%. However, operating expenses have also risen, highlighting the need for careful management moving forward.
Read more →PENPenumbra, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and...
Penumbra, Inc. reported strong financial results for Q4 and the full year 2023, with revenues of $284.7 million for Q4 and $1,058.5 million for the year, reflecting increases of 28.7% and 25.0%, respectively. The company saw significant growth in its thrombectomy products, which drove a 42.4% increase in Q4 sales. Looking ahead, Penumbra projects continued revenue growth of 16% to 20% in 2024, bolstered by its U.S. thrombectomy franchise.
Read more →PENPenumbra, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 22, 2024 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2023 ...
Penumbra, Inc. has announced that it will host a conference call to discuss its financial results for the fourth quarter and full year 2023 on February 22, 2024, after market close. A press release detailing the results will be issued simultaneously. The conference call will be accessible via phone and webcast, allowing investors and stakeholders to engage directly with the company's leadership. This event reflects Penumbra's commitment to maintaining open lines of communication with its investors.
Read more →PENPenumbra, Inc. to Present at the J.P. Morgan 42nd Annual Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the J.P. Morgan 42nd Annual Healthcare Conference on...
Penumbra, Inc. has announced that its management team will present at the J.P. Morgan 42nd Annual Healthcare Conference scheduled for January 8, 2024. The event is significant as it allows Penumbra to highlight its innovative therapies to investors and stakeholders. A webcast of the presentation will be available on the company's website following the event.
Read more →PENFirst Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash™ - for Treatment of Acute Pulmonary Embolism Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced the first patient enrolled in STORM-PE, a...
Penumbra, Inc. has announced the enrollment of the first patient in the STORM-PE trial, a pioneering randomized controlled study evaluating the effectiveness of its Lightning Flash™ technology combined with anticoagulation against standard anticoagulation alone for treating pulmonary embolism (PE). The trial aims to enroll up to 100 participants across 20 sites and seeks to clarify whether this new technology can enhance patient outcomes in acute PE management. Prominent investigators involved emphasize the significance of this study in potentially reshaping treatment guidelines for PE patients.
Read more →PENPenumbra, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 35th Annual Healthcare Conference on ...
Penumbra, Inc. announced its upcoming presentation at the Piper Sandler 35th Annual Healthcare Conference scheduled for November 28, 2023. The management team will discuss the company's innovative therapies and product portfolio, emphasizing its role in addressing challenging medical conditions. A webcast of the presentation will be available for at least two weeks following the event, further supporting transparency with investors.
Read more →PENPenumbra Teams Up with Honor Everywhere to Bring US War Memorials to Aging Veterans Everyday, memories of the people who served in World War II, Vietnam, and the Korean War are disappearing from living history. Virtual reality...
Penumbra, Inc. has collaborated with virtual reality companies through the "Honor Everywhere" program to provide aging and terminally ill veterans with immersive experiences of U.S. war memorials. This initiative aims to preserve the memories of veterans from World War II, Vietnam, and the Korean War by allowing them to virtually visit these memorials, which many can no longer access physically. Penumbra's REAL Immersive System contributes to this effort by enabling veterans to experience their service's commemoration from home. The program is designed as a free resource with open source content shared by multiple contributors.
Read more →PENPenumbra, Inc. Reports Third Quarter 2023 Financial Results Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended ...
Penumbra, Inc. reported strong financial results for Q3 2023, with total revenue of $270.9 million, a 26.8% increase from the previous year. The company saw significant growth in its thrombectomy products, which generated $179.1 million in sales, up 38.0%. Despite increased operating expenses, net income rose to $9.2 million, reflecting improved profitability. The company anticipates continued revenue growth in the upcoming quarter.
Read more →PENPenumbra, Inc. Reports Third Quarter 2023 Financial Results
Penumbra, Inc. reported strong third quarter financial results for 2023, with revenues reaching $270.9 million, an increase of 26.8% year-over-year. The company achieved significant growth in its thrombectomy product line, which generated $179.1 million in revenue, up 38% from the previous year. Net income also improved to $9.2 million, contributing to an adjusted EBITDA of $51.5 million. For the fourth quarter, Penumbra anticipates revenue growth of 28% to 31%, indicating a positive financial outlook for the remainder of the year.
Read more →PENNEW LATE BREAKING DATA DEMONSTRATE PENUMBRA'S COMPUTER ASSISTED VACUUM THROMBECTOMY TECHNOLOGY FOR PULMONARY EMBOLISM IMPROVED PATIENT OUTCOMES Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced the latest STRIKE-PE data evaluating Penumbra's...
Penumbra, Inc. has announced positive interim results from its STRIKE-PE study, demonstrating that its computer-assisted vacuum thrombectomy (CAVT) technology effectively treats pulmonary embolism. The data indicate significant improvements in clinical and functional outcomes for patients, including reduced heart strain and enhanced quality of life. Presented at the VIVA 2023 Conference, the results involved initial evaluations of 150 patients and reinforce the potential of Penumbra's technology as a leading treatment option for pulmonary embolism. Future studies aim to further establish the advantages of CAVT over standard anticoagulation therapies.
Read more →PENPenumbra, Inc. Schedules Third Quarter 2023 Earnings Release and Conference Call for November 2, 2023 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2023 after market...
Penumbra, Inc. has scheduled a conference call for November 2, 2023, to discuss its financial results for the third quarter of 2023. The call is set to take place at 4:30 PM Eastern Time, following the release of a press announcement detailing the financial results. This ongoing communication underscores the company's commitment to transparency and investor relations.
Read more →PENPenumbra, Inc. Reports Second Quarter 2023 Financial Results
Penumbra, Inc. reported strong financial results for the second quarter of 2023, highlighting a revenue increase of 25.5% year-over-year, reaching $261.5 million. The company also reported a shift from operational losses to a profit of $17.9 million. Operating expenses increased, impacting gross margin slightly, but the outlook for the full year is optimistic with an increased revenue guidance of $1.05 billion to $1.07 billion. The growth is expected to continue in the vascular business, while the neuro business may see slower growth.
Read more →PENPenumbra, Inc. Reports Second Quarter 2023 Financial Results Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter...
Penumbra, Inc. reported strong financial results for Q2 2023, with revenues of $261.5 million, reflecting a 25.5% increase from the previous year. The company also achieved a net income of $18.96 million, a notable turnaround from a loss in Q2 2022. Penumbra has raised its revenue guidance for the full year to between $1.05 billion and $1.07 billion, indicating continued growth in its vascular and neuro product segments.
Read more →PENPenumbra, Inc. to Present at the Canaccord Genuity 43rd Annual Growth Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 43rd Annual Growth Conference on ...
Penumbra, Inc. announced that its management team is scheduled to present at the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023. The event will feature a presentation aimed at informing investors and stakeholders about the company's progress. A webcast of the presentation will be accessible on the company's website for at least two weeks following the event, extending reach and engagement.
Read more →PENPenumbra, Inc. Schedules Second Quarter 2023 Earnings Release and Conference Call for August 1, 2023 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2023 after market...
Penumbra, Inc. has announced a conference call scheduled for August 1, 2023, to discuss its financial results for the second quarter of 2023. The call will take place after market close at 4:30 PM Eastern Time. A press release detailing the financial performance will be issued prior to the call, and the event will be accessible via phone or webcast from the company's website.
Read more →PENPenumbra Expands Computer-Aided Thrombectomy Offerings with Lightning Bolt 7 Technology Designed to Rapidly Remove Blood Clots with Modulated Aspiration Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced the U.S. Food and Drug Administration (FDA)...
Penumbra, Inc. has announced the FDA clearance and launch of its advanced thrombectomy system, Lightning Bolt 7. This system utilizes a new modulated aspiration technique designed to efficiently remove large blood clots, significantly minimizing blood loss. Medical professionals assert that this technology marks a significant advancement in treating conditions like acute limb ischemia. Lightning Bolt 7, part of Penumbra's Indigo System, is expected to enhance procedural efficiency and improve patient outcomes markedly.
Read more →PENPenumbra, Inc. to Present at William Blair's 43rd Annual Growth Stock Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at William Blair's 43rd Annual Growth Stock Conference on ...
Penumbra, Inc. will present at William Blair's 43rd Annual Growth Stock Conference on June 7, 2023. The event will allow the management team to share insights about their innovative therapies and product portfolio. A webcast of the presentation will be accessible for at least two weeks post-event, facilitating investor engagement and transparency. This appearance underscores Penumbra's commitment to communicating with healthcare providers and investors.
Read more →PENPenumbra, Inc. Reports First Quarter 2023 Financial Results
Penumbra, Inc. reported strong financial results for the first quarter of 2023, with revenues reaching $241.4 million, reflecting an 18.4% increase year-over-year. The company's gross profit was $151.1 million, maintaining a similar gross margin as the previous year. Despite rising operating expenses, the company achieved a profit from operations of $8.0 million compared to a loss in the same quarter last year. Penumbra has updated its 2023 revenue outlook to expect total revenues between $1.04 billion and $1.06 billion, indicating robust growth prospects.
Read more →PENPenumbra, Inc. Schedules First Quarter 2023 Earnings Release and Conference Call for May 2, 2023 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2023 after market...
Penumbra, Inc. has announced a conference call scheduled for May 2, 2023, to discuss its financial results for the first quarter of 2023. The call will occur after market close at 4:30 PM Eastern Time. Investors can access the call via phone or through a webcast available on the company's website. This event highlights the company's commitment to keeping stakeholders informed about its performance.
Read more →PENPenumbra and Veterans Health Administration to Expand Access to Rehabilitative Care using Virtual Reality Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced that it will collaborate with the Veterans...
Penumbra, Inc. has announced a collaboration with the Veterans Health Administration to develop and implement virtual reality solutions for rehabilitative care. This partnership aims to address critical rehabilitation needs of veterans and enhance access to care, particularly in remote areas. Penumbra's REAL y-Series technology will be the foundation of this initiative, focusing on neurorehabilitation and chronic condition management. The collaboration is expected to improve therapeutic interventions through innovative VR tools, thereby promoting better health outcomes for veterans.
Read more →PENPenumbra, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
Penumbra, Inc. reported strong financial results for the fourth quarter and full year of 2022, with revenue increasing by 8.4% for Q4 and by 13.3% for the full year. The company projects significant growth for 2023, anticipating total revenues to exceed $1 billion. While operating expenses did increase, the overall gross profit margin improved, reflecting effective capital management. The outlook remains optimistic, but the company also noted challenges with net income compared to the previous year.
Read more →PENPenumbra, Inc. to Present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT ...
Penumbra, Inc. has announced its participation in Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference, scheduled for March 2, 2023. Management will present their innovative therapies aimed at addressing significant medical needs. The presentation will also be accessible via a webcast for two weeks post-event, ensuring wider reach and engagement with investors and the public.
Read more →PENPenumbra, Inc. Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 23, 2023 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2022 ...
Penumbra, Inc. has announced that it will release its financial results for the fourth quarter and full year of 2022 on February 23, 2023, followed by a conference call at 4:30 PM Eastern Time. This event is part of Penumbra's commitment to communicate openly with investors regarding their financial performance. The conference call will be accessible by phone and through a webcast on their website, ensuring widespread access to the discussion. The company is recognized for its innovative medical therapies and operates globally in more than 100 countries.
Read more →PENPENUMBRA LAUNCHES LATEST INNOVATION IN MECHANICAL THROMBECTOMY: LIGHTNING FLASH™ Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced the U.S. Food and Drug Administration (FDA)...
Penumbra, Inc. has announced the FDA clearance and launch of Lightning Flash™, an advanced mechanical thrombectomy system designed to efficiently remove large blood clots. Featuring novel technologies such as dual clot detection algorithms and MaxID hypotube technology, Lightning Flash aims to improve patient outcomes by facilitating quicker and less invasive procedures. The device is expected to encourage wider adoption of thrombectomy techniques among physicians, as it can handle a broad spectrum of clot types. This innovation is set to transform the standard of care for patients suffering from severe thromboembolic conditions.
Read more →PENPenumbra, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on...
ALAMEDA, Calif. , Dec. 19, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 . Event: 41 st Annual J.P. Morgan Healthcare Conference D
Read more →PENPenumbra, Inc. Reports Third Quarter 2022 Financial Results
Penumbra, Inc. Reports Third Quarter 2022 Financial Results ALAMEDA, Calif., November 3, 2022 PR Newswire - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2022. R
Read more →PEN▼ -5.6%on this newsshared move
Penumbra, Inc. to Present at the Jefferies London Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Jefferies London Healthcare Conference on Tuesday, ...
ALAMEDA, Calif. , Nov. 1, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 . An audio webcast of the presentation will be available by vis
Read more →PENPenumbra, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 3, 2022 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2022 after market...
ALAMEDA, Calif. , Oct. 6, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the third quarter 2022 after market close on Thursday, November 3, 2022 at 4:30 PM Eastern Time . A press release with t
Read more →PENPenumbra, Inc. Reports Second Quarter 2022 Financial Results
Penumbra, Inc. Reports Second Quarter 2022 Financial Results ALAMEDA, Calif., August 4, 2022 PR Newswire - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2022. Revenu
Read more →PENPenumbra, Inc. to Present at the Canaccord Genuity 42nd Annual Growth Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 42nd Annual Growth Conference on ...
ALAMEDA, Calif. , July 27, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 . A webcast of the presentation will be available by
Read more →PEN▲ +6.7%on this news
Penumbra, Inc. Schedules Second Quarter 2022 Earnings Release and Conference Call for August 4, 2022 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2022 after market...
ALAMEDA, Calif. , July 7, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the second quarter 2022 after market close on Thursday, August 4, 2022 at 4:30 PM Eastern Time . A press release with se
Read more →PENPenumbra, Inc. Reports First Quarter 2022 Financial Results
Penumbra, Inc. Reports First Quarter 2022 Financial Results ALAMEDA, Calif., May 3, 2022 PR Newswire - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2022. Revenue of
Read more →PENPenumbra, Inc. to Present at the Bank of America Securities 2022 Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Bank of America Securities 2022 Healthcare...
ALAMEDA, Calif. , April 26, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10, 2022. A webcast of the presentation will be available by
Read more →PENPenumbra, Inc. Schedules First Quarter 2022 Earnings Release and Conference Call for May 3, 2022 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2022 after market...
ALAMEDA, Calif. , April 5, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the first quarter 2022 after market close on Tuesday, May 3, 2022 at 4:30 PM Eastern Time . A press release with first
Read more →PENPenumbra, Inc. to Present at the 21st Annual Needham Virtual Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference...
ALAMEDA, Calif. , March 28, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the 21 st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 . Event: 21 st Annual Needham Virtual Healthcare Conf
Read more →PENPenumbra, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results ALAMEDA, CA
Penumbra, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results ALAMEDA, CA, February 22, 2022 (PR Newswire) - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year
Read more →PENPenumbra, Inc. to Present at Citi's 2022 Virtual Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at Citi's 2022 Virtual Healthcare Conference on Thursday, ...
ALAMEDA, Calif. , Feb. 10, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at Citi's 2022 Virtual Healthcare Conference on Thursday, February 24, 2022 . Event: Citi's 2022 Virtual Healthcare Conference Date: Thurs
Read more →PENPenumbra, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 22, 2022 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2021 ...
ALAMEDA, Calif. , Feb. 1, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2021 after market close on Tuesday, February 22, 2022 at 4:30 PM Eastern Time . A press
Read more →PENPenumbra, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on...
ALAMEDA, Calif. , Dec. 22, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the 40 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 . Event: 40 th Annual J.P. Morgan Healthcare Conference
Read more →PENPenumbra, Inc. Reports Third Quarter 2021 Financial Results
Penumbra, Inc. Reports Third Quarter 2021 Financial Results ALAMEDA, Calif., November 3, 2021 PR Newswire - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2021. R
Read more →PENPenumbra, Inc. Schedules Third Quarter 2021 Earnings Release and Conference Call for November 3, 2021 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2021 after market...
ALAMEDA, Calif. , Oct. 6, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the third quarter 2021 after market close on Wednesday, November 3, 2021 at 4:30 PM Eastern Time. A press release with t
Read more →PENPenumbra, Inc. to Present at the Morgan Stanley 19th Annual Global Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Morgan Stanley 19th Annual Global Healthcare...
ALAMEDA, Calif. , Aug. 31, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021 . Event: Morgan Stanley 19th Annual Global H
Read more →PENPenumbra, Inc. to Present at the 2021 Wells Fargo Virtual Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 2021 Wells Fargo Virtual Healthcare Conference on...
ALAMEDA, Calif. , Aug. 26, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the 2021 Wells Fargo Virtual Healthcare Conference on Thursday, September 9, 2021 . Event: 2021 Wells Fargo Virtual Healthcare Conferen
Read more →PENPenumbra, Inc. Reports Second Quarter 2021 Financial Results
Penumbra, Inc. Reports Second Quarter 2021 Financial Results ALAMEDA, Calif., August 9, 2021 PR Newswire - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2021. Revenu
Read more →PENPenumbra, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 41st Annual Growth Conference on ...
ALAMEDA, Calif. , July 28, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 . A webcast of the presentation will be available by
Read more →PENPenumbra, Inc. Schedules Second Quarter 2021 Earnings Release and Conference Call for August 9, 2021 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2021 after market...
ALAMEDA, Calif. , July 12, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the second quarter 2021 after market close on Monday, August 9, 2021 at 4:30 PM Eastern Time. A press release with seco
Read more →PENPenumbra, Inc. to Present at the William Blair 41st Annual Growth Stock Virtual Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair 41st Annual Growth Stock Virtual...
ALAMEDA, Calif. , May 18, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the William Blair 41st Annual Growth Stock Virtual Conference on Tuesday, June 1, 2021 . Event: William Blair 41st Annual Growth Stock V
Read more →PENPenumbra, Inc. Reports First Quarter 2021 Financial Results
Penumbra, Inc. Reports First Quarter 2021 Financial Results ALAMEDA, Calif., May 4, 2021 (PR Newswire) - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2021. Revenue
Read more →PENPenumbra, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2021 Virtual Health Care...
ALAMEDA, Calif. , April 27, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 . Event: BofA Securities 2021 Virtual Health Care Con
Read more →PENPenumbra, Inc. Schedules First Quarter 2021 Earnings Release and Conference Call for May 4, 2021 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2021 after market...
ALAMEDA, Calif. , April 13, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the first quarter 2021 after market close on Tuesday, May 4, 2021 at 4:30 PM Eastern Time. A press release with first
Read more →PENPenumbra, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results ALAMEDA, CA
Penumbra, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results ALAMEDA, CA, February 23, 2021 (PR Newswire) - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year
Read more →PENPenumbra, Inc. to Present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at Citi's 2021 Healthcare Services, Medtech, Tools, &...
ALAMEDA, Calif. , Feb. 10, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on Wednesday, February 24, 2021 . Event: Citi's 2021 Healthc
Read more →PENPenumbra, Inc. Schedules Fourth Quarter and Full Year 2020 Earnings Release and Conference Call for February 23, 2021 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2020 ...
ALAMEDA, Calif. , Feb. 2, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2020 after market close on Tuesday, February 23, 2021 at 4:30 PM Eastern Time . A press
Read more →PENPenumbra Announces Preliminary Unaudited Revenue for the Fourth Quarter and Full Year 2020 Penumbra, Inc. (the Company ) (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced certain unaudited...
ALAMEDA, Calif. , Jan. 11, 2021 /PRNewswire/ -- Penumbra, Inc. (the "Company") ( NYSE: PEN ), a global healthcare company focused on innovative therapies, today announced certain unaudited preliminary revenue results for the fourth quarter and full year 2020 ahead of its particip
Read more →PENDocument Penumbra Announces Preliminary Unaudited Revenue for the Fourth Quarter and Full Year 2020
Penumbra Announces Preliminary Unaudited Revenue for the Fourth Quarter and Full Year 2020 ALAMEDA, Calif. January 11, 2021 PRNewswire -- Penumbra, Inc. (the "Company") (NYSE PEN), a global healthcare company focused on innovative therapies, today announced certain unaudited pre
Read more →PENPenumbra, Inc. to Present at the 39th Annual J.P. Morgan Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on...
ALAMEDA, Calif. , Dec. 29, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 . An audio webcast of the presentation will be available
Read more →PENPenumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall
Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall ALAMEDA, Calif., Dec. 15, 2020 PRNewswire -- Penumbra, Inc. (NYSE PEN) today announced that it is voluntarily recalling all configurations of the Penumbra JET 7 Reperfusion Catheter
Read more →PENPenumbra Responds to False Allegations from Short Sellers Seeking to Manipulate Company Stock and Remove Life-saving Medical Devices from the Market
Penumbra Responds to False Allegations from Short Sellers Seeking to Manipulate Company Stock and Remove Life-saving Medical Devices from the Market ALAMEDA, Calif. - December 8, 2020 - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today
Read more →PENPenumbra, Inc. to Participate in CEO Discussion with Bank of America Penumbra, Inc. (NYSE: PEN) today announced that its chief executive officer is scheduled to participate in a discussion with Bank of America on...
ALAMEDA, Calif. , Dec. 4, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its chief executive officer is scheduled to participate in a discussion with Bank of America on Tuesday, December 8, 2020 . Event: CEO Discussion with Bank of America Date: Tuesday, D
Read more →PENPenumbra Announces Partnership with RapidAI to Enable Faster Clinical Decision-Making for Pulmonary Embolism Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced a new partnership to develop solutions to...
"PE is at the precipice of a transformation in how patients affected by this condition are being treated. Several advances have been made during the last few years largely due to the PERT Consortium's efforts, combined with innovation in therapeutic options," said Robert Lookstei
Read more →PENPenumbra, Inc. to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity Virtual MedTech & Diagnostics...
ALAMEDA, Calif. , Nov. 6, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 . Event: Canaccord Genuity Virtual MedTech & Di
Read more →PENPenumbra, Inc. Reports Third Quarter 2020 Financial Results
Penumbra, Inc. Reports Third Quarter 2020 Financial Results ALAMEDA, Calif., October 28, 2020 (PR Newswire) - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2020.
Read more →PENPenumbra, Inc. Schedules Third Quarter 2020 Earnings Release and Conference Call for October 28, 2020 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2020 after market...
ALAMEDA, Calif. , Sept. 29, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the third quarter 2020 after market close on Wednesday, October 28, 2020 at 4:30 PM Eastern Time. Penumbra is hosting
Read more →PENPenumbra, Inc. to Present at the Morgan Stanley 18th Annual Global Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Morgan Stanley 18th Annual Global Healthcare...
ALAMEDA, Calif. , Sept. 3, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Morgan Stanley 18th Annual Global Healthcare Conference on Thursday, September 17, 2020 . Event: Morgan Stanley 18th Annual Global
Read more →PENPenumbra, Inc. to Present at the Wells Fargo 2020 Virtual Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Wells Fargo 2020 Virtual Healthcare Conference on...
ALAMEDA, Calif. , Aug. 26, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Wells Fargo 2020 Virtual Healthcare Conference on Wednesday, September 9, 2020 . Event: Wells Fargo 2020 Virtual Healthcare Confere
Read more →PENPenumbra, Inc. Reports Second Quarter 2020 Financial Results
Penumbra, Inc. Reports Second Quarter 2020 Financial Results ALAMEDA, Calif., August 3, 2020 (PR Newswire) - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2020. Reve
Read more →PENPenumbra, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 40th Annual Growth Conference on ...
ALAMEDA, Calif. , July 29, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12, 2020 . Event: Canaccord Genuity 40th Annual Growth Confere
Read more →PENPenumbra, Inc. Schedules Second Quarter 2020 Earnings Release and Conference Call for August 3, 2020 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2020 after market...
ALAMEDA, Calif. , July 20, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the second quarter 2020 after market close on Monday, August 3, 2020 at 4:30 PM Eastern Time. A press release with seco
Read more →PENPenumbra, Inc. to Present at the William Blair 40th Annual Growth Stock Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair 40th Annual Growth Stock Conference...
ALAMEDA, Calif. , May 29, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the William Blair 40th Annual Growth Stock Conference on Tuesday, June 9, 2020 . A webcast of the presentation will be available by visi
Read more →PENPenumbra, Inc. Announces Launch of Offering of $100,000,000 of Shares of its Common Stock Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced that it has commenced an underwritten public ...
ALAMEDA, Calif. , May 27, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global healthcare company focused on innovative therapies, today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares of commo
Read more →PENPenumbra, Inc. Announces Pricing of Offering of Common Stock Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the pricing of an underwritten public...
ALAMEDA, Calif. , May 27, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global healthcare company focused on innovative therapies, today announced the pricing of an underwritten public offering of 753,012 shares of its common stock at a price to the public of $166.00 per sh
Read more →PENPenumbra, Inc. Announces Virtual 2020 Annual Meeting of Stockholders Penumbra, Inc. (NYSE: PEN) today announced that the format for its 2020 Annual Meeting of Stockholders (the Annual Meeting ) has been changed from...
ALAMEDA, Calif. , May 15, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that the format for its 2020 Annual Meeting of Stockholders (the "Annual Meeting") has been changed from an in-person meeting to a virtual-only meeting at the previously announced date and
Read more →PENPenumbra Announces Management Transition Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced that Sri Kosaraju, President, will...
ALAMEDA, Calif. , May 12, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global healthcare company focused on innovative therapies, today announced that Sri Kosaraju , President, will transition from Penumbra, and Jason Mills joins as Executive Vice President, Strategy. Mr.
Read more →PENPenumbra Announces Management Transition Sri Kosaraju will transition from his role as President to join nonprofit focused on COVID-19 testing will remain advisor to CEO Adam Elsesser Jason Mills, a seasoned Wall Street
Penumbra Announces Management Transition Sri Kosaraju will transition from his role as President to join nonprofit focused on COVID-19 testing will remain advisor to CEO Adam Elsesser Jason Mills, a seasoned Wall Street Senior Analyst from Canaccord Genuity, joins Penumbra lead
Read more →PENPenumbra, Inc. Reports First Quarter 2020 Financial Results
Penumbra, Inc. Reports First Quarter 2020 Financial Results ALAMEDA, Calif., May 7, 2020 (PR Newswire) - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2020. Revenue
Read more →PENPenumbra, Inc. to Present at the Bank of America Merrill Lynch 2020 Health Care Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Bank of America Merrill Lynch 2020 Health Care...
ALAMEDA, Calif. , April 29, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Bank of America Merrill Lynch 2020 Health Care Conference on Wednesday, May 13, 2020 . A webcast of the presentation will be avail
Read more →PENPenumbra, Inc. Schedules First Quarter 2020 Earnings Release and Conference Call for May 7, 2020 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2020 after market...
ALAMEDA, Calif. , April 23, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the first quarter 2020 after market close on Thursday, May 7, 2020 at 5:00 PM Eastern Time. A press release with first
Read more →PENPenumbra Provides Update on COVID-19 Response and Impact
Penumbra Provides Update on COVID-19 Response and Impact Provides Preliminary Revenue Range for the First Quarter 2020 and Withdraws Prior Annual Revenue Guidance for 2020 Due to COVID-19 Impact ALAMEDA, Calif., April 6, 2020 PRNewswire -- Penumbra, Inc. (NYSE PEN), a global he
Read more →PENPenumbra, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and...
ALAMEDA, Calif. , Feb. 25, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2019 . Financial Highlights: Fourth Quarter 2019 Fi
Read more →PENPenumbra, Inc. Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for February 25, 2020 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2019 ...
ALAMEDA, Calif. , Feb. 11, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2019 after market close on Tuesday, February 25, 2020 at 5:00 PM Eastern Time. A press
Read more →PENPenumbra, Inc. to Present at the 38th Annual J.P. Morgan Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference in...
ALAMEDA, Calif. , Dec. 31, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the 38 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 14 , 2020. A webcast of the presentation wi
Read more →PENMaggie Yuen Appointed Chief Financial Officer Of Penumbra Following the Promotion of Sri Kosaraju to President in August, Maggie Yuen will assume responsibilities as chief financial officer and Lambert Shiu will become c
Maggie Yuen Appointed Chief Financial Officer Of Penumbra Following the Promotion of Sri Kosaraju to President in August, Maggie Yuen will assume responsibilities as chief financial officer and Lambert Shiu will become chief accounting officer. ALAMEDA, Calif., November 25, 201
Read more →PENPenumbra, Inc. Announces Investor Day 2019 Penumbra, Inc. (NYSE: PEN) today announced that it will host an Investor Day on Tuesday, December 3, 2019 in Boston, MA at 8:30am Eastern Time....
ALAMEDA, Calif. , Nov. 19, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host an Investor Day on Tuesday, December 3, 2019 in Boston, MA at 8:30am Eastern Time . Webcast & Conference Call Information A webcast of the event can be accessed on the "
Read more →PENPenumbra, Inc. Reports Third Quarter 2019 Financial Results
Penumbra, Inc. Reports Third Quarter 2019 Financial Results ALAMEDA, Calif., November 7, 2019 (PR Newswire) - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2019.
Read more →PENPenumbra, Inc. Schedules Third Quarter 2019 Earnings Release and Conference Call for November 7, 2019 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2019 after market...
ALAMEDA, Calif. , Oct. 17, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the third quarter 2019 after market close on Thursday, November 7, 2019 at 4:30 PM Eastern Time . A press release with
Read more →PENSri Kosaraju Promoted to President and CFO of Penumbra Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the promotion of Sri Kosaraju to President,...
ALAMEDA, Calif. , Aug. 29, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global healthcare company focused on innovative therapies, today announced the promotion of Sri Kosaraju to President, in addition to his current responsibilities as CFO of Penumbra. Kosaraju joined Pe
Read more →PENPenumbra, Inc. to Present at the Morgan Stanley 17th Annual Global Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Morgan Stanley 17th Annual Global Healthcare...
ALAMEDA, Calif. , Aug. 27, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Morgan Stanley 17 th Annual Global Healthcare Conference in New York, NY on Tuesday, September 10 , 2019. A webcast of the presenta
Read more →PENPenumbra, Inc. to Present at the 2019 Wells Fargo Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 2019 Wells Fargo Healthcare Conference in Boston,...
ALAMEDA, Calif. , Aug. 21, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the 2019 Wells Fargo Healthcare Conference in Boston, MA on Wednesday, September 4 , 2019. Event: 2019 Wells Fargo Healthcare Conferenc
Read more →PENPenumbra, Inc. Reports Second Quarter 2019 Financial Results
Penumbra, Inc. Reports Second Quarter 2019 Financial Results ALAMEDA, Calif., August 6, 2019 (PR Newswire) - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2019. Reve
Read more →PENPenumbra, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 39th Annual Growth Conference in ...
ALAMEDA, Calif. , July 17, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Canaccord Genuity 39th Annual Growth Conference in Boston, MA on Wednesday, August 7 , 2019. Event: Canaccord Genuity 39th Annual G
Read more →PENPenumbra, Inc. Schedules Second Quarter 2019 Earnings Release and Conference Call for August 6, 2019 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2019 after market...
ALAMEDA, Calif. , July 16, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the second quarter 2019 after market close on Tuesday, August 6, 2019 at 4:30 PM Eastern Time . A press release with se
Read more →PENPenumbra, Inc. to Present at the BMO 2019 Prescriptions for Success Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BMO 2019 Prescriptions for Success Healthcare...
ALAMEDA, Calif. , June 11, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the BMO 2019 Prescriptions for Success Healthcare Conference in New York, NY on Tuesday, June 25 , 2019. Event: BMO 2019 Prescriptions
Read more →PENPenumbra, Inc. to Present at the Goldman Sachs 40th Annual Global Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Goldman Sachs 40th Annual Global Healthcare...
ALAMEDA, Calif. , May 29, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Goldman Sachs 40 th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 11 , 2019. A webcast of the pres
Read more →PENPenumbra, Inc. Reports First Quarter 2019 Financial Results
Penumbra, Inc. Reports First Quarter 2019 Financial Results ALAMEDA, Calif., May 7, 2019 (PR Newswire) - Penumbra, Inc. (NYSE PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2019. Revenue
Read more →PENPenumbra, Inc. to Present at the Bank of America Merrill Lynch 2019 Health Care Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Bank of America Merrill Lynch 2019 Health Care...
ALAMEDA, Calif. , May 1, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV on Wednesday, May 15 , 2019. A webcast of the presentation
Read more →PENPenumbra, Inc. Schedules First Quarter 2019 Earnings Release and Conference Call for May 7, 2019 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2019 after market...
ALAMEDA, Calif. , April 17, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the first quarter 2019 after market close on Tuesday, May 7, 2019 at 4:30 PM Eastern Time. A press release with first
Read more →PENPenumbra, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results ALAMEDA, CA
Penumbra, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results ALAMEDA, CA, February 26, 2019 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full yea
Read more →PENPenumbra, Inc. Schedules Fourth Quarter and Full Year 2018 Earnings Release and Conference Call for February 26, 2019 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2018 ...
ALAMEDA, Calif. , Jan. 30, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2018 after market close on Tuesday, February 26, 2019 at 4:30 PM Eastern Time. A press
Read more →PENPenumbra, Inc. Appoints Janet Leeds and Surbhi Sarna to its Board of Directors Penumbra, Inc. (NYSE: PEN) today announced that two new Board members were appointed to its Board of Directors (the Board ) on January 17, 2019. Ms. ...
ALAMEDA, Calif. , Jan. 18, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that two new Board members were appointed to its Board of Directors (the "Board") on January 17, 2019 . Ms. Janet Leeds was appointed to the Board as a Class I director, effective immediat
Read more →PENPenumbra, Inc. to Present at the 37th Annual J.P. Morgan Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in...
ALAMEDA, Calif. , Dec. 20, 2018 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 8 , 2019. A webcast of the presentation wil
Read more →PENPenumbra, Inc. to Present at the BMO Prescriptions for Success Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BMO Prescriptions for Success Healthcare...
ALAMEDA, Calif. , Nov. 29, 2018 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the BMO Prescriptions for Success Healthcare Conference in New York, NY on Wednesday, December 12 , 2018. A webcast of the presentation
Read more →PENPenumbra, Inc. Reports Third Quarter 2018 Financial Results
Penumbra, Inc. Reports Third Quarter 2018 Financial Results ALAMEDA, Calif., November 5, 2018 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2018.
Read more →PENPenumbra, Inc. Schedules Third Quarter 2018 Earnings Release and Conference Call for November 5, 2018 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2018 after market...
ALAMEDA, Calif. , Oct. 15, 2018 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the third quarter 2018 after market close on Monday, November 5, 2018 at 5:00 PM Eastern Time. A press release with thi
Read more →PENPenumbra, Inc. Announces Participation at Upcoming Investor Conferences Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following upcoming investor conferences: Event:...
ALAMEDA, Calif. , Aug. 22, 2018 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the following upcoming investor conferences: Event: 2018 Wells Fargo Healthcare Conference Location: Boston, MA at The Westin Copley Pl
Read more →PENPenumbra, Inc. Reports Second Quarter 2018 Financial Results
Penumbra, Inc. Reports Second Quarter 2018 Financial Results ALAMEDA, Calif., August 7, 2018 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2018. Sec
Read more →PENPenumbra, Inc. to Present at the Canaccord Genuity 38th Annual Growth Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 38th Annual Growth Conference in ...
ALAMEDA, Calif. , July 19, 2018 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Canaccord Genuity 38th Annual Growth Conference in Boston, MA on Wednesday, August 8 , 2018. A webcast of the presentation will be
Read more →PENPenumbra, Inc. Schedules Second Quarter 2018 Earnings Release and Conference Call for August 7, 2018 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2018 after market...
ALAMEDA, Calif. , July 17, 2018 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the second quarter 2018 after market close on Tuesday, August 7, 2018 at 4:30 PM Eastern Time. A press release with sec
Read more →PENPenumbra, Inc. to Present at the Goldman Sachs 39th Annual Global Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Goldman Sachs 39th Annual Global Healthcare...
ALAMEDA, Calif. , May 29, 2018 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 12 , 2018. A webcast of the prese
Read more →PENPenumbra, Inc. Reports First Quarter 2018 Financial Results
Penumbra, Inc. Reports First Quarter 2018 Financial Results ALAMEDA, Calif., May 8, 2018 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2018. First Q
Read more →PENPenumbra, Inc. to Present at the Bank of America Merrill Lynch 2018 Health Care Conference ALAMEDA, Calif., May 2, 2018 /PRNewswire/ – Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Bank...
ALAMEDA, Calif. , May 2, 2018 /PRNewswire/ – Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV on Wednesday, May 16 , 2018. A webcast of the presentation
Read more →PENPenumbra, Inc. Schedules First Quarter 2018 Earnings Release and Conference Call for May 8, 2018 Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2018 after market...
ALAMEDA, Calif. , April 18, 2018 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the first quarter 2018 after market close on Tuesday, May 8, 2018 at 4:30 PM Eastern Time. A press release with first
Read more →PENPenumbra, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results ALAMEDA, CA
Penumbra, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results ALAMEDA, CA, February 27, 2018 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full yea
Read more →PENPenumbra, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference in...
ALAMEDA, Calif. , Dec. 21, 2017 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the 36 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 9 , 2018. A webcast of the presentation wil
Read more →PENPenumbra, Inc. Reports Third Quarter 2017 Financial Results
Penumbra, Inc. Reports Third Quarter 2017 Financial Results ALAMEDA, Calif., November 7, 2017 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on interventional therapies, today reported financial results for the third quarter ended September 30, 2
Read more →PENPenumbra, Inc. Schedules Third Quarter 2017 Earnings Release and Conference Call for November 7, 2017 at 5:00 PM Eastern Time Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2017 after market...
ALAMEDA, Calif. , Oct. 24, 2017 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the third quarter 2017 after market close on Tuesday, November 7, 2017 at 5:00 PM Eastern Time. A press release with th
Read more →PENPenumbra, Inc. Reports Second Quarter 2017 Financial Results
Penumbra, Inc. Reports Second Quarter 2017 Financial Results ALAMEDA, Calif., August 8, 2017 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on interventional therapies, today reported financial results for the second quarter ended June 30, 2017.
Read more →PENPenumbra, Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 37th Annual Growth Conference in ...
ALAMEDA, Calif. , July 25, 2017 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Canaccord Genuity 37th Annual Growth Conference in Boston, MA on Wednesday, August 9 , 2017. A webcast of the presentation will be
Read more →PENPenumbra, Inc. Schedules Second Quarter 2017 Earnings Release and Conference Call for August 8, 2017 at 4:30 PM Eastern Time Penumbra, Inc.(NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2017 after market...
ALAMEDA, Calif. , July 25, 2017 /PRNewswire/ -- Penumbra, Inc.(NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the second quarter 2017 after market close on Tuesday, August 8, 2017 at 4:30 PM Eastern Time. A press release with seco
Read more →PENPenumbra, Inc. Promotes Daniel Davis to Chief Commercial Officer ALAMEDA, Calif., July 5, 2017 /PRNewswire/ – Penumbra, Inc. (NYSE: PEN) today announced that Daniel Davis has been promoted and will add the title of ...
ALAMEDA, Calif. , July 5, 2017 /PRNewswire/ – Penumbra, Inc. (NYSE: PEN ) today announced that Daniel Davis has been promoted and will add the title of Chief Commercial Officer to his existing title of President, North America . Mr. Davis joined Penumbra in 2007 as one of the fir
Read more →PENPenumbra, Inc. Reports First Quarter 2017 Financial Results
Penumbra, Inc. Reports First Quarter 2017 Financial Results ALAMEDA, Calif., May 9, 2017 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on interventional therapies, today reported financial results for the first quarter ended March 31, 2017. Fir
Read more →PENPenumbra, Inc. to Present at the Bank of America Merrill Lynch 2017 Health Care Conference Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on interventional therapies, today announced that its management team is scheduled to ...
ALAMEDA, Calif. , May 3, 2017 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global healthcare company focused on interventional therapies, today announced that its management team is scheduled to present at the Bank of America Merrill Lynch 2017 Health Care Conference in Las Veg
Read more →PENPenumbra, Inc. Schedules First Quarter 2017 Earnings Release and Conference Call for May 9, 2017 at 4:30 PM Eastern Time Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2017 after market...
ALAMEDA, Calif. , April 25, 2017 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the first quarter 2017 after market close on Tuesday, May 9, 2017 at 4:30 PM Eastern Time. A press release with first
Read more →PENPenumbra, Inc. Appoints Bridget O'Rourke to its Board of Directors Penumbra, Inc. (NYSE: PEN) today announced that Bridget O'Rourke has been appointed to its Board of Directors, effective immediately. Ms. O'Rourke...
ALAMEDA, Calif. , April 21, 2017 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that Bridget O'Rourke has been appointed to its Board of Directors, effective immediately. Ms. O'Rourke has held a number of executive and leadership positions over more than twenty year
Read more →PENPenumbra, Inc. Announces Pricing of Offering of 1,300,000 Shares of its Common Stock Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on interventional therapies, today announced the pricing of an underwritten public...
ALAMEDA, Calif. , March 16, 2017 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global healthcare company focused on interventional therapies, today announced the pricing of an underwritten public offering of 1,300,000 shares of its common stock at a price to the public of $76.00
Read more →PENPenumbra, Inc. Announces Launch of Offering of 1,300,000 Shares of its Common Stock Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on interventional therapies, today announced that it has commenced an underwritten...
ALAMEDA, Calif. , March 15, 2017 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global healthcare company focused on interventional therapies, today announced that it has commenced an underwritten public offering of 1,300,000 shares of its common stock. All of the shares of commo
Read more →PENPenumbra, Inc. Reports Fourth Quarter and Full Year 2016 Financial Results ALAMEDA, CA
Penumbra, Inc. Reports Fourth Quarter and Full Year 2016 Financial Results ALAMEDA, CA, February 28, 2017 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on interventional therapies, today reported financial results for the fourth quarter and full
Read more →PENPenumbra, Inc. Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for February 28, 2017 at 5:00 PM Eastern Time Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and year ended...
ALAMEDA, Calif. , Feb. 14, 2017 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the fourth quarter and year ended December 31, 2016 , after market close on Tuesday, February 28, 2017 at 5:00 PM Easte
Read more →PENPenumbra, Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced that its management team is scheduled to present at the 35th...
ALAMEDA, Calif. , Dec. 20, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global interventional therapies company, today announced that its management team is scheduled to present at the 35 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. A webcast of the p
Read more →PENPenumbra, Inc. Appoints Thomas C. Wilder to its Board of Directors Penumbra, Inc. (NYSE: PEN) today announced that Thomas C. Wilder has been appointed to its Board of Directors, effective January 13, 2017. Mr. Wilder ...
ALAMEDA, Calif. , Dec. 19, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that Thomas C. Wilder has been appointed to its Board of Directors, effective January 13, 2017 . Mr. Wilder will serve on the board for a term expiring at Penumbra's 2019 annual meeting of
Read more →PENPenumbra, Inc. Announces Resignation of Board Member Penumbra, Inc. (NYSE: PEN) today announced that Kevin Sullivan has tendered his resignation from the company's Board of Directors for personal health ...
ALAMEDA, Calif. , Nov. 15, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that Kevin Sullivan has tendered his resignation from the company's Board of Directors for personal health reasons, effective immediately. "Kevin's contributions to Penumbra have been imm
Read more →PENPenumbra, Inc. Reports Third Quarter 2016 Financial Results
Penumbra, Inc. Reports Third Quarter 2016 Financial Results ALAMEDA, Calif., November 3, 2016 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today reported financial results for the third quarter ended September 30, 2016. Third Quarter 20
Read more →PENPenumbra, Inc. to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced that its management team is scheduled to present at the...
ALAMEDA, Calif. , Oct. 27, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global interventional therapies company, today announced that its management team is scheduled to present at the Canaccord Genuity Medical Technologies & Diagnostics Forum in New York, NY . An audio w
Read more →PENPenumbra, Inc. Schedules Third Quarter 2016 Earnings Release and Conference Call for November 3, 2016 at 5:00 PM Eastern Time Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter ended September 30, ...
ALAMEDA, Calif. , Oct. 20, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the third quarter ended September 30, 2016 , after market close on Thursday, November 3, 2016 at 5:00 PM Eastern Time.
Read more →PENPenumbra, Inc. Announces Participation at Upcoming Investor Conferences Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced that its management team is scheduled to present at the...
ALAMEDA, Calif. , Aug. 18, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global interventional therapies company, today announced that its management team is scheduled to present at the following upcoming investor conferences: An audio webcast of each presentation will be
Read more →PENPenumbra, Inc. Reports Second Quarter 2016 Financial Results
Penumbra, Inc. Reports Second Quarter 2016 Financial Results ALAMEDA, Calif., August 9, 2016 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today reported financial results for the second quarter ended June 30, 2016. Second Quarter 2016 F
Read more →PENPenumbra, Inc. to Present at the Canaccord Genuity 36th Annual Growth Conference Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced that its management team is scheduled to present at the...
ALAMEDA, Calif. , July 15, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global interventional therapies company, today announced that its management team is scheduled to present at the Canaccord Genuity 36 th Annual Growth Conference in Boston, Massachusetts . Event: Cana
Read more →PENPenumbra, Inc. Schedules Second Quarter 2016 Earnings Release and Conference Call for August 9, 2016 at 4:30 PM Eastern Time Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter ended June 30,...
ALAMEDA, Calif. , July 15, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the second quarter ended June 30, 2016 , after market close on Tuesday, August 9, 2016 at 4:30 PM Eastern Time. A press
Read more →PENPenumbra, Inc. Reports First Quarter 2016 Financial Results
Penumbra, Inc. Reports First Quarter 2016 Financial Results ALAMEDA, Calif., May 9, 2016 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today reported financial results for the first quarter ended March 31, 2016. First Quarter 2016 Financ
Read more →PENPenumbra, Inc. to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced that its management team is scheduled to present at the Bank...
ALAMEDA, Calif. , April 27, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global interventional therapies company, today announced that its management team is scheduled to present at the Bank of America Merrill Lynch Healthcare Conference at the Encore at Wynn, Las Vegas, N
Read more →PENPenumbra, Inc. Schedules First Quarter 2016 Earnings Release and Conference Call for May 9, 2016 at 4:30 PM Eastern Time Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter ended March 31,...
ALAMEDA, Calif. , April 25, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the first quarter ended March 31, 2016 , after market close on Monday, May 9, 2016 at 4:30 PM Eastern Time. A press re
Read more →PENPenumbra, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results
Penumbra, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results ALAMEDA, Calif., March 8, 2016 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today reported financial results for the fourth quarter and full year ended December 3
Read more →PENPenumbra, Inc. Schedules Fourth Quarter and Full Year 2015 Earnings Release and Conference Call for March 8, 2016 at 4:30 PM Eastern Time Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and year ended...
ALAMEDA, Calif. , Feb. 23, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss financial results for the fourth quarter and year ended December 31, 2015 , after market close on Tuesday, March 8, 2016 at 4:30 PM Eastern T
Read more →PENPenumbra, Inc. Appoints Kevin Sullivan to its Board of Directors Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, announced today that Kevin J. Sullivan has been appointed to its board of...
ALAMEDA, Calif. , Feb. 23, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) , a global interventional therapies company, announced today that Kevin J. Sullivan has been appointed to its board of directors, effective immediately. Mr. Sullivan will serve on the board for a term expi
Read more →PENPenumbra, Inc. to Present at the 34th Annual J.P. Morgan 2016 Healthcare Conference Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced that its management team is scheduled to present at the 34th...
ALAMEDA, Calif. , Dec. 28, 2015 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ), a global interventional therapies company, today announced that its management team is scheduled to present at the 34 th Annual J.P. Morgan 2016 Healthcare Conference in San Francisco, CA at the Westin S
Read more →PENPenumbra, Inc. Reports Third Quarter 2015 Financial Results Penumbra, Inc.(NYSE: PEN), a global interventional therapies company, today reported financial results for the third quarter ended September 30, 2015....
ALAMEDA, Calif. , Nov. 12, 2015 /PRNewswire/ -- Penumbra, Inc.(NYSE: PEN ), a global interventional therapies company, today reported financial results for the third quarter ended September 30, 2015 . Third Quarter 2015 Financial Results Total revenue grew to $50.4 million for
Read more →PENPenumbra, Inc.
Penumbra, Inc. Reports Third Quarter 2015 Financial Results ALAMEDA, Calif., November 12, 2015 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today reported financial results for the third quarter ended September 30, 2015. Third Quarter 2
Read more →PENPenumbra, Inc. Schedules Third Quarter 2015 Earnings Release and Conference Call for November 12, 2015 at 4:30 PM Eastern Time Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss third quarter 2015 financial results after market close on...
ALAMEDA, Calif. , Oct. 30, 2015 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that it will host a conference call to discuss third quarter 2015 financial results after market close on Thursday, November 12, 2015 at 4:30 PM Eastern Time. A press release with third qu
Read more →Competitive Position
How PEN ranks across every disease it competes inCompetitive Position is a premium feature
See how PEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial